CAPECITABINE GLENMARK 150 mg FILM-COATED TABLETS

Introduction

Package Leaflet:information for the user

Capecitabine Glenmark 150 mg film-coated tablets EFG

capecitabine

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Capecitabine Glenmark and what is it used for
2. What you need to know before you take Capecitabine Glenmark
3. How to take Capecitabine Glenmark
4. Possible side effects
5. Storage of Capecitabine Glenmark
6. Contents of the pack and other information

1. What is Capecitabine Glenmark and what is it used for

Capecitabine belongs to a group of medicines called “cytostatic medicines”, which stop the growth of cancer cells. This medicine contains capecitabine and is not a cytostatic medicine itself. Only after being absorbed into the body does it change into an active anti-cancer medicine (more in tumor tissue than in normal tissue).

Capecitabine is used for the treatment of colon, rectal, gastric, or breast cancer. Additionally, this medicine is used to prevent the reappearance of colon cancer after the complete removal of the tumor through surgery.

Capecitabine can be used alone or in combination with other medicines.

2. What you need to know before you take Capecitabine Glenmark

Do not take Capecitabine Glenmark:

• if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6). You should inform your doctor if you have any kind of allergy or exaggerated reaction to this medicine,
• if you have previously had severe reactions to fluoropyrimidine treatment (a group of cancer medicines like fluorouracil),
• if you are pregnant or breastfeeding,
• if you have very low levels of white blood cells or platelets in your blood (leukopenia, neutropenia, or thrombocytopenia),
• if you have severe liver or kidney disease,
• if you know you have no activity of the enzyme dihydropyrimidine dehydrogenase (DPD) (complete DPD deficiency),
• if you are being treated or have been treated in the last 4 weeks with brivudine as part of the treatment for herpes zoster (shingles or chickenpox).

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medicine

• if you know you have a partial deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD)
• if you have a family member with a partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD)
• if you have liver or kidney disease
• if you have heart problems, for example, an irregular heartbeat or chest and back pain caused by physical exertion and due to problems with blood flow to the heart
• if you have brain diseases (for example, cancer that has spread to the brain, or nerve damage (neuropathy))
• if you have a calcium imbalance (see blood tests)
• if you have diabetes
• if you are unable to keep food or water in your body due to nausea and vomiting
• if you have diarrhea
• if you are dehydrated or become dehydrated
• if you have an electrolyte imbalance in your blood (electrolyte imbalance, see analysis)
• if you have a history of eye problems, as you will need extra monitoring of your eyes
• if you have a severe skin reaction.

DPD deficiency

DPD deficiency is a genetic condition that is not usually related to health problems unless you are being treated with certain medicines. If you have a DPD deficiency and take capecitabine, you have a higher risk of serious side effects (indicated in section 4. Possible side effects). It is recommended that you undergo a test to detect DPD deficiency before starting treatment. If you have no enzyme activity, you should not take Capecitabine Glenmark. If you have reduced enzyme activity (partial deficiency), your doctor may prescribe a reduced dose. Although the results of the test for DPD deficiency are negative, serious or potentially fatal side effects may still occur.

Children and adolescents

Capecitabine is not indicated in children and adolescents. Do not administer Capecitabine to children and adolescents.

Use of Capecitabine Glenmark with other medicines

Inform your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is very important, as taking more than one medicine at the same time can enhance or weaken their effects.

You must not take brivudine (an antiviral medicine for the treatment of shingles or chickenpox) at the same time as you are being treated with capecitabine (including any rest period when you are not taking any Capecitabine Glenmark tablets).

If you have taken brivudine, you must wait at least 4 weeks after finishing brivudine before starting to take capecitabine. See also the section “Do not take Capecitabine Glenmark”.

You also need to be very careful if you are taking any of the following medicines:

• medicines for gout (allopurinol),
• medicines to reduce blood clotting (coumarin, warfarin),
• medicines for seizures or tremors (phenytoin),
• interferon alpha,
• radiotherapy and certain medicines used for cancer treatment (folinic acid, oxaliplatin, bevacizumab, cisplatin, irinotecan),
• medicines used to treat folic acid deficiency.

Taking Capecitabine Glenmark with food and drinks

You should take this medicine within 30 minutes after finishing a meal.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You must not take this medicine if you are pregnant or think you may be pregnant.

You must not breastfeed your baby while taking this medicine and for 2 weeks after the last dose.

If you are a woman who could become pregnant, you must use a reliable contraceptive method during treatment with Capecitabine Glenmark and for 6 months after the last dose.

If you are a male patient and your female partner could become pregnant, you must use a reliable contraceptive method during treatment with Capecitabine Glenmark and for 3 months after the last dose.

Driving and using machines

While taking capecitabine, you may feel dizzy, nauseous, or tired. Therefore, capecitabine may affect your ability to drive or use machines.

Capecitabine Glenmark contains anhydrous lactose

If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.

Capecitabine Glenmark contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.

3. How to take Capecitabine Glenmark

Follow exactly the administration instructions of this medicine as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist.

Capecitabine should only be prescribed by a doctor with experience in the use of cancer medicines.

Your doctor will prescribe a treatment schedule and the correct dose for you. The dose of capecitabine depends on your body surface area. This is calculated by measuring your height and weight. The usual dose for adults is 1,250 mg/m2 of body surface area twice a day (morning and evening). Here are two examples: a person weighing 64 kg and measuring 1.64 m has a body surface area of 1.7 m2, so they should take 4 tablets of 500 mg and 1 tablet of 150 mg twice a day. A person weighing 80 kg and measuring 1.80 m has a body surface area of 2.0 m2, so they should take 5 tablets of 500 mg twice a day.

Your doctor will tell you what dose you need to take, when you need to take it, and for how long you need to take it.

Your doctor may instruct you to take a combination of 150 mg and 500 mg tablets for each dose.

• Take the tablets in the morning and evening, as prescribed by your doctor.
• Take the tablets within 30 minutes after finishing a meal or snack, and swallow them whole with water. Do not crush or split the tablets. If you cannot swallow the Capecitabine Glenmark tablets whole, tell your healthcare professional.
• It is important that you take all your medication as prescribed by your doctor.

Capecitabine tablets are usually taken for 14 days followed by a 7-day rest period (during which no tablets are taken). This 21-day period is a treatment cycle.

In combination with other medicines, the usual dose in adults may be less than 1,250 mg/m2 of body surface area, and you may need to take the tablets for a different period (for example, every day, without a rest period).

If you take more Capecitabine Glenmark than you should

If you take more capecitabine than you should, contact your doctor as soon as possible before taking the next dose.

You may experience the following side effects if you take more capecitabine than you should: feeling unwell, diarrhea, inflammation or ulcers in the stomach or mouth, pain or bleeding in the intestine or stomach, or bone marrow depression (reduction of certain types of blood cells). Inform your doctor immediately if you experience any of these symptoms.

In case of overdose, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Capecitabine Glenmark

Do not take the missed dose. Do not take a double dose to make up for missed doses. Instead, continue your usual dosing schedule and consult your doctor.

If you stop taking Capecitabine Glenmark

Stopping treatment with capecitabine does not produce side effects. If you are taking anticoagulant medicines (e.g., acenocoumarol), stopping treatment with capecitabine may require your doctor to adjust the dose of the anticoagulant.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

STOPtaking Capecitabina Glenmark immediately and contact your doctor if any of these symptoms appear:

• Diarrhea: if you have an increase of 4 or more bowel movements compared to your normal daily bowel movements or have nocturnal diarrhea.
• Vomiting: if you vomit more than once in a 24-hour period.
• Nausea: if you lose your appetite and the amount of food you eat each day is much less than usual.
• Stomatitis: if you have pain, redness, swelling, or ulcers in the mouth and/or throat.
• Skin Reaction on Hands and Feet: if you have pain, swelling, and redness or tingling in hands and/or feet.
• Fever: if you have a temperature of 38°C or higher.
• Infection: if you have signs of infection caused by bacteria or viruses or other organisms.
• Chest Pain: if you have localized pain in the center of the chest, especially if it occurs while exercising.
• Steven-Johnson Syndrome: if you have painful red or purple rashes that spread and blisters and other lesions that start to appear on the mucous membrane (e.g., mouth and lips), particularly if you have had sensitivity to light, respiratory infections (e.g., bronchitis), and/or fever before.
• Angioedema:seek medical attention immediately if you notice any of the following symptoms; you may need urgent medical treatment: swelling mainly of the face, lips, tongue, or throat that makes swallowing or breathing difficult, itching, and rashes. It could be a sign of angioedema.

Detected in time, these adverse effects usually improve within 2 or 3 days of interrupting treatment. However, if these adverse effects continue, contact your doctor immediately. Your doctor may advise you to resume treatment with a lower dose.

If you present severe stomatitis (irritation in the mouth and/or throat), mucosal inflammation, diarrhea, neutropenia (increased risk of infections), or neurotoxicity during the first treatment cycle, there may be a DPD deficiency (see Section 2: Warnings and Precautions).

The skin reaction on hands and feet can lead to the loss of fingerprints, which can affect your identification through fingerprint analysis.

In addition to the above, when this medicine is used alone, very frequent adverse effects that may affect more than 1 in 10 people are:

• abdominal pain
• rash, dry or itchy skin
• fatigue
• loss of appetite (anorexia)

These adverse effects can be serious; therefore, always contact your doctor immediately when you start to feel an adverse effect. Your doctor may advise you to reduce the dose and/or temporarily stop treatment with this medicine. This will help reduce the likelihood of the adverse effect continuing or becoming serious.

Other adverse effects are:

Frequent adverse effects (may affect up to 1 in 10 people) include:

• decrease in the number of white or red blood cells (seen in blood tests)
• dehydration, weight loss
• sleeplessness (insomnia), depression
• headache, drowsiness, dizziness, strange sensation in the skin (tingling or numbness), taste disturbances
• eye irritation, increased tearing, redness of the eyes (conjunctivitis)
• vein inflammation (thrombophlebitis)
• difficulty breathing, nasal bleeding, cough, runny nose
• cold sores or infections from other herpes
• lung or respiratory tract infections (e.g., pneumonia or bronchitis)
• intestinal bleeding, constipation, pain in the upper abdomen, indigestion, gas (increased flatulence), dry mouth
• skin rashes, hair loss (alopecia), redness of the skin, dry skin, itching (pruritus), skin color changes, skin loss, skin inflammation, nail disorders
• joint pain, or pain in the limbs, chest, or back
• fever, swelling of the limbs, feeling unwell
• liver function problems (seen in blood tests) and increased bilirubin in the blood (excreted by the liver)

Infrequent adverse effects (may affect up to 1 in 100 people) include:

• blood infection, urinary tract infection, skin infection, nose and throat infection, fungal infections (including those of the mouth), flu, gastroenteritis, dental abscesses
• skin inflammation (lipomas)
• decrease in blood cells, including platelets, dilution of blood (seen in blood tests)
• allergies
• diabetes, decrease in potassium, magnesium, or calcium in the blood, increase in blood sugar
• confusion, panic attacks, depression, decreased libido
• difficulty speaking, memory problems, loss of motor coordination, balance disorder, fainting, nerve damage (neuropathy), and sensation problems
• blurred or double vision
• vertigo, ear pain
• irregular heartbeats and palpitations (arrhythmias), chest pain, and heart attack (myocardial infarction)
• blood clots in deep veins, high or low blood pressure, hot flashes, cold extremities, purple spots on the skin
• blood clots in the pulmonary veins (pulmonary embolism), lung collapse, coughing up blood, asthma, exertional dyspnea
• intestinal obstruction, fluid accumulation in the abdomen, inflammation of the small or large intestine, stomach, or esophagus, lower abdominal pain, abdominal discomfort, acid reflux, blood in the stool
• jaundice (yellowing of the skin and eyes)
• skin ulcers and blisters, sunburn-like skin reaction, redness of the palms, swelling, or pain in the face
• joint or stiffness swelling, bone pain, muscle weakness or stiffness
• fluid accumulation in the kidneys, increased urination frequency at night, incontinence, blood in the urine, increased creatinine in the blood (sign of kidney dysfunction)
• unusual vaginal bleeding
• swelling (edema), chills, and stiffness

Some of these adverse effects are more frequent when capecitabine is used with other cancer medications. Other observed adverse effects are:

Frequent adverse effects (may affect up to 1 in 10 people) include:

• decrease in sodium, magnesium, or calcium in the blood, increase in blood sugar
• neuropathic pain
• ringing or buzzing in the ears (tinnitus), hearing loss
• vein inflammation
• hoarseness, voice changes
• pain or altered sensation in the mouth, jaw pain
• sweating, night sweats
• muscle spasms
• difficulty urinating, blood or protein in the urine
• bruises or reactions at the injection site (caused by medications administered by injection at the same time)

Rare adverse effects (may affect up to 1 in 1,000 people) are:

• narrowing or obstruction of the tear duct (stenosis of the tear duct)
• liver failure
• inflammation leading to dysfunction or obstruction of bile secretion (cholestatic hepatitis)
• specific changes in the electrocardiogram (QT interval prolongation)
• certain types of arrhythmias (including ventricular fibrillation, torsades de pointes, and bradycardia)
• Eye inflammation that causes eye pain and possible vision problems
• Skin inflammation that causes red scaly patches due to an immune system disease
• Angioedema (swelling mainly of the face, lips, tongue, or throat, itching, and rashes)

Very rare adverse effects (may affect up to 1 in 10,000 people) are:

• severe skin reactions such as skin rashes, ulcers, and blisters that may involve ulcers in the mouth, nose, genitals, hands, feet, and eyes (red and swollen eyes)

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Capecitabina Glenmark

Keep this medicine out of sight and reach of children.

Do not use this medicine after the expiration date that appears on the box and blister after CAD. The expiration date is the last day of the month indicated.

Store below 25°C.

Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Capecitabina Glenmark

The active ingredient is capecitabine. Each film-coated tablet contains 150 mg of capecitabine.

The other components are

• Tablet core: anhydrous lactose (see section 2), microcrystalline cellulose, hypromellose, sodium croscarmellose, magnesium stearate.
• Tablet coating: hypromellose, talc, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172).

Appearance of the Product and Package Contents

Light pink film-coated tablet, capsule-shaped, biconvex, 11.5 mm long and 5.5 mm wide, with the mark "CAP" on one side and "150" on the other.

Capecitabina Glenmark film-coated tablets are available in PVC/PVdC/aluminum blisters in transparent packaging.

Package sizes:

Blister package: 60 film-coated tablets (6 blisters of 10 tablets)

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Glenmark Arzneimittel GmbH

Industriestr. 31

82194 Gröbenzell

Germany

Manufacturer:

Apis labor GmbH

Resslstraße 9

Ebenthal in Kärnten, 9065

Austria.

You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:

Glenmark Farmacéutica, S.L.U.

C/ Retama 7, 7th floor

28045 Madrid

Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Denmark Capecitabin Zentiva 500 mg film-coated tablets

Germany Capecitabin Glenmark 150 mg film-coated tablets

Spain Capecitabina Glenmark 150 mg film-coated tablets EFG

Sweden Capecitabin Zentiva 500 mg film-coated tablets

Date of the last revision of thisprospectus:March 2022.

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es)